Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study of Roginolisib in Combination with Dostarlimab with or Without Docetaxel in Patients with Advanced Non-squamous NSCLC Who Have Progressed on Standard of Care Immune Checkpoint Therapy and Platinum Doublet Chemotherapy or Standard Immunotherapy Without Chemotherapy (PULMO-1)

Next Previous
Trial Profile

A Phase I/IIa Study of Roginolisib in Combination with Dostarlimab with or Without Docetaxel in Patients with Advanced Non-squamous NSCLC Who Have Progressed on Standard of Care Immune Checkpoint Therapy and Platinum Doublet Chemotherapy or Standard Immunotherapy Without Chemotherapy (PULMO-1)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Dostarlimab (Primary) ; Roginolisib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PULMO-01
  • Sponsors iOnctura

Most Recent Events

  • 08 May 2025 According to an iOnctura media release, company announced it has dosed the first patient in this trial.
  • 02 May 2025 Planned initiation date changed from 1 Apr 2025 to 1 May 2025.
  • 02 May 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top